PHAXIAM Therapeutics S.A.
CIK 0001624422
Revenue (TTM)
€0
Q2 Jun 2023
Net Income (TTM)
−€228K
+99.6% YoY
Q2 Jun 2023
EPS Diluted (TTM)
−€0.01
+99.6% YoY
Q2 Jun 2023
Gross Margin
—
Q2 Jun 2023
Operating Margin
—
Q2 Jun 2023
Net Margin
—
Q2 Jun 2023
Free Cash Flow (TTM)
—
Q2 Jun 2023
Cash
€25.19M
Q2 Jun 2023
Total Debt
—
Q2 Jun 2023
Shares Outstanding
31.02M sh
Q2 Jun 2023
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.